Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
Heron Therapeutics (Nasdaq: HRTX) has appointed Brett Fleshman as Chief Business Officer. With 25 years of experience in corporate and business development, commercial strategy, and marketing, Fleshman is expected to drive inorganic revenue growth and expand investor relations. CEO Craig Collard emphasized the timing for adding substantial BD and M&A experience to the management team.
Fleshman's background includes roles at NovaQuest Capital Management, Veloxis Pharmaceuticals, and Cornerstone Therapeutics, where he contributed to successful turnarounds and acquisitions. His focus has been on developing efficient strategies for commercializing new products and revitalizing distressed assets. Fleshman's appointment aims to leverage Heron's established commercial team in hospital and community settings.
Heron Therapeutics (Nasdaq: HRTX) ha nominato Brett Fleshman come Chief Business Officer. Con 25 anni di esperienza nello sviluppo aziendale, strategia commerciale e marketing, Fleshman è atteso per guidare la crescita dei ricavi inorganici e ampliare le relazioni con gli investitori. Il CEO Craig Collard ha sottolineato l'importanza di integrare significative esperienze in BD e M&A nel team di gestione.
Il background di Fleshman comprende ruoli in NovaQuest Capital Management, Veloxis Pharmaceuticals e Cornerstone Therapeutics, dove ha contribuito a turnaround e acquisizioni di successo. Si è concentrato sullo Sviluppo di strategie efficaci per la commercializzazione di nuovi prodotti e il rilancio di beni in difficoltà. L’obiettivo della nomina di Fleshman è sfruttare il team commerciale consolidato di Heron negli ospedali e nelle comunità.
Heron Therapeutics (Nasdaq: HRTX) ha nombrado a Brett Fleshman como Director de Negocios. Con 25 años de experiencia en desarrollo corporativo y de negocios, estrategia comercial y marketing, se espera que Fleshman impulse el crecimiento de ingresos inorgánicos y amplíe las relaciones con los inversores. El CEO Craig Collard enfatizó la importancia de añadir experiencia sustancial en BD y M&A al equipo directivo.
La trayectoria de Fleshman incluye roles en NovaQuest Capital Management, Veloxis Pharmaceuticals y Cornerstone Therapeutics, donde contribuyó a exitosos reestructuramientos y adquisiciones. Su enfoque ha estado en desarrollar estrategias eficaces para comercializar nuevos productos y revitalizar activos en dificultades. El nombramiento de Fleshman tiene como objetivo aprovechar el equipo comercial establecido de Heron en entornos hospitalarios y comunitarios.
헤론 테라퓨틱스(Nasdaq: HRTX)는 브렛 플래시맨을 최고 비즈니스 책임자로 임명했습니다. 25년의 기업 및 비즈니스 개발, 상업 전략 및 마케팅 경험을 갖춘 플래시맨은 비인기 수익 성장을 추진하고 투자자 관계를 확장할 것으로 기대됩니다. CEO 크레이그 콜라드는 경영진 팀에 실질적인 BD 및 M&A 경험을 추가하는 것이 중요하다고 강조했습니다.
플래시맨의 배경에는 노바퀘스트 캐피탈 매니지먼트, 벨록시스 제약, 그리고 코너스톤 테라퓨틱스에서 근무한 경험이 있으며, 여기서 성공적인 전환과 인수에 기여했습니다. 그는 신제품 상용화 및 어려움에 처한 자산 revitalization을 위한 효율적인 전략 개발에 집중해왔습니다. 플래시맨의 임명은 병원 및 지역사회 환경에서 헤론의 확립된 상업 팀을 활용하는 것을 목표로 하고 있습니다.
Heron Therapeutics (Nasdaq: HRTX) a nommé Brett Fleshman au poste de Chief Business Officer. Fort de 25 ans d'expérience en développement corporatif et commercial, en stratégie et en marketing, Fleshman est attendu pour impulser la croissance des revenus inorganiques et étendre les relations avec les investisseurs. Le PDG Craig Collard a souligné l'importance d'ajouter une expérience significative en BD et M&A à l'équipe de direction.
Le parcours de Fleshman inclut des postes chez NovaQuest Capital Management, Veloxis Pharmaceuticals et Cornerstone Therapeutics, où il a contribué à des redressements et des acquisitions réussis. Son objectif a été de développer des stratégies efficaces pour la commercialisation de nouveaux produits et la revitalisation d'actifs en difficulté. La nomination de Fleshman vise à tirer parti de l'équipe commerciale établie de Heron dans les hôpitaux et les communautés.
Heron Therapeutics (Nasdaq: HRTX) hat Brett Fleshman zum Chief Business Officer ernannt. Mit 25 Jahren Erfahrung in der Unternehmens- und Geschäftsentwicklung, in der kommerziellen Strategie und im Marketing wird von Fleshman erwartet, dass er das Wachstum der inorganischen Einnahmen vorantreibt und die Beziehungen zu Investoren ausbaut. CEO Craig Collard betonte die Bedeutung, erhebliche Erfahrungen in den Bereichen BD und M&A ins Management-Team zu integrieren.
Fleshmans Hintergrund umfasst Positionen bei NovaQuest Capital Management, Veloxis Pharmaceuticals und Cornerstone Therapeutics, wo er zu erfolgreichen Umstrukturierungen und Übernahmen beigetragen hat. Sein Fokus lag auf der Entwicklung effizienter Strategien zur Vermarktung neuer Produkte und zur Wiederbelebung von notleidenden Vermögenswerten. Die Ernennung von Fleshman zielt darauf ab, das etablierte Vertriebsteam von Heron im Krankenhaus- und Gemeindeumfeld zu nutzen.
- Appointment of experienced Chief Business Officer with 25 years in corporate and business development
- Focus on driving substantial inorganic revenue growth
- Expansion of investor relations to reach strategic biopharma and generalist investors
- New CBO's track record in successful turnarounds and acquisitions
- None.
"Now is the right time to add substantial BD and M&A experience to the management team at Heron, and I welcome Brett to repeat the success we have enjoyed together in the past," said Craig Collard, Chief Executive Officer of Heron. "Brett will be focused on driving substantial inorganic revenue growth to leverage our established commercial team in the hospital and community settings. He will also lead our investor relations function with the goal of expanding our reach to strategic biopharma and generalist investors."
Most recently, Brett Fleshman served as Managing Director at NovaQuest Capital Management, a leader in product-based financing for late-stage clinical and commercial biopharmaceutical programs. While at NovaQuest, Brett was responsible for deal sourcing, structuring nondilutive investments, negotiations, diligence, and post-close investment management. Prior to NovaQuest, Mr. Fleshman served as Vice President of Strategy and Corporate Development for Veloxis Pharmaceuticals, where he helped formulate a turnaround commercialization strategy which led to the company's acquisition in 2020 by Asahi Kasei. Previously, Mr. Fleshman held senior commercial and business development roles at Cornerstone Therapeutics, supporting numerous company acquisitions, asset purchases and territory licenses to build thriving hospital and rare disease businesses that helped lead to the company's acquisition by Chiesi Pharmaceutici S.p.A. Throughout his career, Mr. Fleshman has focused on developing efficient strategies for commercializing new products and revitalizing distressed assets. Earlier in his career, Mr. Fleshman also held senior marketing roles at Ther-Rx Corporation and Genzyme Biosurgery, now Sanofi Genzyme. Mr. Fleshman earned a degree in Business Administration from the John M. Olin School of Business at
"In the field of M&A we strive for opportunities to deliver on a mandate for bringing products to such a comprehensive yet specialized commercial team," said Mr. Fleshman. "Working with Craig and many members of this team extensively in the past, we had a reputation for a healthy cadence of deals and delivering strong commercial results. It's great to be back and to offer Heron the experience and contacts gained while financing late-stage and commercial pharmaceutical companies."
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Brett Fleshman
Chief Business Officer
Heron Therapeutics, Inc.
bfleshman@herontx.com
858-251-4400
View original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-announces-appointment-of-brett-fleshman-as-chief-business-officer-302236304.html
SOURCE Heron Therapeutics, Inc.
FAQ
Who is the new Chief Business Officer of Heron Therapeutics (HRTX)?
What is Brett Fleshman's primary focus as CBO at Heron Therapeutics (HRTX)?
What is Brett Fleshman's professional background before joining Heron Therapeutics (HRTX)?
How many years of experience does Brett Fleshman bring to Heron Therapeutics (HRTX)?
